235 related articles for article (PubMed ID: 37388233)
1. A phase II randomized clinical trial to assess toxicity and quality of life of breast cancer patients with hypofractionated versus conventional fractionation radiotherapy with regional nodal irradiation in the context of COVID-19 crisis.
Gil GOB; de Andrade WP; Diniz PHC; Cantidio FS; Queiroz IN; Gil MLBV; Almeida CAM; Caldeira PPR; Regalin M; Silva-Filho AL
Front Oncol; 2023; 13():1202544. PubMed ID: 37388233
[TBL] [Abstract][Full Text] [Related]
2. HYPofractionated Adjuvant RadioTherapy in 1 versus 2 weeks in high-risk patients with breast cancer (HYPART): a non-inferiority, open-label, phase III randomised trial.
Yadav BS; Dahiya D; Kannan P; Goyal S; Laroiya I; Irrinki S; Singh NR; Sharma R
Trials; 2024 Jan; 25(1):21. PubMed ID: 38167339
[TBL] [Abstract][Full Text] [Related]
3. Acute and Short-term Toxic Effects of Conventionally Fractionated vs Hypofractionated Whole-Breast Irradiation: A Randomized Clinical Trial.
Shaitelman SF; Schlembach PJ; Arzu I; Ballo M; Bloom ES; Buchholz D; Chronowski GM; Dvorak T; Grade E; Hoffman KE; Kelly P; Ludwig M; Perkins GH; Reed V; Shah S; Stauder MC; Strom EA; Tereffe W; Woodward WA; Ensor J; Baumann D; Thompson AM; Amaya D; Davis T; Guerra W; Hamblin L; Hortobagyi G; Hunt KK; Buchholz TA; Smith BD
JAMA Oncol; 2015 Oct; 1(7):931-41. PubMed ID: 26247543
[TBL] [Abstract][Full Text] [Related]
4. One versus three weeks hypofractionated whole breast radiotherapy for early breast cancer treatment: the FAST-Forward phase III RCT.
Brunt AM; Haviland JS; Wheatley DA; Sydenham MA; Bloomfield DJ; Chan C; Cleator S; Coles CE; Donovan E; Fleming H; Glynn D; Goodman A; Griffin S; Hopwood P; Kirby AM; Kirwan CC; Nabi Z; Patel J; Sawyer E; Somaiah N; Syndikus I; Venables K; Yarnold JR; Bliss JM;
Health Technol Assess; 2023 Nov; 27(25):1-176. PubMed ID: 37991196
[TBL] [Abstract][Full Text] [Related]
5. Ultra-hypofractionated versus conventionally fractionated radiotherapy for prostate cancer (HYPO-RT-PC): patient-reported quality-of-life outcomes of a randomised, controlled, non-inferiority, phase 3 trial.
Fransson P; Nilsson P; Gunnlaugsson A; Beckman L; Tavelin B; Norman D; Thellenberg-Karlsson C; Hoyer M; Lagerlund M; Kindblom J; Ginman C; Johansson B; Björnlinger K; Seke M; Agrup M; Zackrisson B; Kjellén E; Franzén L; Widmark A
Lancet Oncol; 2021 Feb; 22(2):235-245. PubMed ID: 33444529
[TBL] [Abstract][Full Text] [Related]
6. Ultra-hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: 5-year outcomes of the HYPO-RT-PC randomised, non-inferiority, phase 3 trial.
Widmark A; Gunnlaugsson A; Beckman L; Thellenberg-Karlsson C; Hoyer M; Lagerlund M; Kindblom J; Ginman C; Johansson B; Björnlinger K; Seke M; Agrup M; Fransson P; Tavelin B; Norman D; Zackrisson B; Anderson H; Kjellén E; Franzén L; Nilsson P
Lancet; 2019 Aug; 394(10196):385-395. PubMed ID: 31227373
[TBL] [Abstract][Full Text] [Related]
7. Quality of life after breast-conserving therapy and adjuvant radiotherapy for non-low-risk ductal carcinoma in situ (BIG 3-07/TROG 07.01): 2-year results of a randomised, controlled, phase 3 trial.
King MT; Link EK; Whelan TJ; Olivotto IA; Kunkler I; Westenberg AH; Gruber G; Schofield P; Chua BH;
Lancet Oncol; 2020 May; 21(5):685-698. PubMed ID: 32203696
[TBL] [Abstract][Full Text] [Related]
8. Preliminary results of hypofractionated radiotherapy in breast cancer in Chandigarh, India: single-centre, non-inferiority, open-label, randomised, phase 3 trial.
Yadav BS; Dahiya D; Gupta M; Gupta A; Oinam AS; Khare S; Irrinki S; Robert N; Sakaray YR; Nagaraj SS; Kumari R
Lancet Reg Health Southeast Asia; 2024 May; 24():100392. PubMed ID: 38550605
[TBL] [Abstract][Full Text] [Related]
9. Intensity-modulated fractionated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-B): acute toxicity findings from an international, randomised, open-label, phase 3, non-inferiority trial.
Brand DH; Tree AC; Ostler P; van der Voet H; Loblaw A; Chu W; Ford D; Tolan S; Jain S; Martin A; Staffurth J; Camilleri P; Kancherla K; Frew J; Chan A; Dayes IS; Henderson D; Brown S; Cruickshank C; Burnett S; Duffton A; Griffin C; Hinder V; Morrison K; Naismith O; Hall E; van As N;
Lancet Oncol; 2019 Nov; 20(11):1531-1543. PubMed ID: 31540791
[TBL] [Abstract][Full Text] [Related]
10. Hypofractionated versus conventionally fractionated radiotherapy for patients with prostate cancer (HYPRO): acute toxicity results from a randomised non-inferiority phase 3 trial.
Aluwini S; Pos F; Schimmel E; van Lin E; Krol S; van der Toorn PP; de Jager H; Dirkx M; Alemayehu WG; Heijmen B; Incrocci L
Lancet Oncol; 2015 Mar; 16(3):274-83. PubMed ID: 25656287
[TBL] [Abstract][Full Text] [Related]
11. Hypofractionated versus conventional intensity-modulated radiation irradiation (HARVEST-adjuvant): study protocol for a randomised non-inferior multicentre phase III trial.
Xie J; Xu F; Zhao Y; Cai G; Lin X; Zhu Q; Lin Q; Yao Y; Xu C; Cai R; Wang S; Tang X; Chen C; Zheng S; Chen M; Chen M; Qian X; Shen C; Li J; Xu H; Xu F; Han Y; Li M; Ou D; Shen KW; Qi WX; Cao L; Huang X; Chen J
BMJ Open; 2022 Sep; 12(9):e062034. PubMed ID: 36581983
[TBL] [Abstract][Full Text] [Related]
12. Conventional versus hypofractionated postmastectomy radiotherapy: a report on long-term outcomes and late toxicity.
Chitapanarux I; Klunklin P; Pinitpatcharalert A; Sripan P; Tharavichitkul E; Nobnop W; Onchan W; Chakrabandhu S; Jia-Mahasap B; Euathrongchit J; Wannasopha Y; Srisuwan T
Radiat Oncol; 2019 Oct; 14(1):175. PubMed ID: 31610801
[TBL] [Abstract][Full Text] [Related]
13. Patient preference study comparing hypofractionated versus conventionally fractionated whole-breast irradiation after breast-conserving surgery.
Kawaguchi H; Tsujino K; Miki M; Matsumoto Y; Ota Y; Hirokaga K; Takao S; Soejima T; Sasaki R
Jpn J Clin Oncol; 2019 Jun; 49(6):545-553. PubMed ID: 30796835
[TBL] [Abstract][Full Text] [Related]
14. Five-year results of a prospective case series of accelerated hypofractionated whole breast radiation with concomitant boost to the surgical bed after conserving surgery for early breast cancer.
Cante D; Franco P; Sciacero P; Girelli G; Marra AM; Pasquino M; Russo G; Borca VC; Mondini G; Paino O; Barmasse R; Tofani S; Numico G; La Porta MR; Ricardi U
Med Oncol; 2013 Jun; 30(2):518. PubMed ID: 23460537
[TBL] [Abstract][Full Text] [Related]
15. Five-Year Longitudinal Analysis of Patient-Reported Outcomes and Cosmesis in a Randomized Trial of Conventionally Fractionated Versus Hypofractionated Whole-Breast Irradiation.
Weng JK; Lei X; Schlembach P; Bloom ES; Shaitelman SF; Arzu IY; Chronowski G; Dvorak T; Grade E; Hoffman K; Perkins G; Reed VK; Shah SJ; Stauder MC; Strom EA; Tereffe W; Woodward WA; Hortobagyi GN; Hunt KK; Buchholz TA; Smith BD
Int J Radiat Oncol Biol Phys; 2021 Oct; 111(2):360-370. PubMed ID: 33992718
[TBL] [Abstract][Full Text] [Related]
16. Hypofractionated Nodal Radiation Therapy for Breast Cancer Was Not Associated With Increased Patient-Reported Arm or Brachial Plexopathy Symptoms.
Leong N; Truong PT; Tankel K; Kwan W; Weir L; Olivotto IA
Int J Radiat Oncol Biol Phys; 2017 Dec; 99(5):1166-1172. PubMed ID: 29165285
[TBL] [Abstract][Full Text] [Related]
17. A Phase 2 Study of 2 Weeks of Adjuvant Whole Breast/Chest Wall and/or Regional Nodal Radiation Therapy for Patients With Breast Cancer.
Yadav BS; Sharma SC
Int J Radiat Oncol Biol Phys; 2018 Mar; 100(4):874-881. PubMed ID: 29485066
[TBL] [Abstract][Full Text] [Related]
18. Conventional Versus Different Hypofractionated Radiotherapy Dosage Schedules in Postmastectomy Advanced Breast Cancer.
Jain N; Sharma R; Sachdeva K; Kaur A; Sudan M
J Med Phys; 2022; 47(2):141-144. PubMed ID: 36212213
[TBL] [Abstract][Full Text] [Related]
19. Hypofractionated Simultaneous Integrated Boost Radiotherapy Versus Conventional Fractionation Radiotherapy of Early Breast Cancer After Breast-Conserving Surgery: Clinical Observation and Analysis.
Dong J; Yang Y; Han D; Zhao Q; Liu C; Sun H; Wang Z; Lin H; Huang W
Technol Cancer Res Treat; 2021; 20():15330338211064719. PubMed ID: 34898315
[No Abstract] [Full Text] [Related]
20. Hypofractionated versus conventionally fractionated radiotherapy for patients with prostate cancer (HYPRO): late toxicity results from a randomised, non-inferiority, phase 3 trial.
Aluwini S; Pos F; Schimmel E; Krol S; van der Toorn PP; de Jager H; Alemayehu WG; Heemsbergen W; Heijmen B; Incrocci L
Lancet Oncol; 2016 Apr; 17(4):464-474. PubMed ID: 26968359
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
